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Gene regulationThe aryl hydrocarbon receptor repressor (AHRR) inhibits the transcription of the aryl hydrocarbon
receptor (AHR) by binding to XRE. We report that AHRR expression is inhibited by tristetraprolin
(TTP), an AU-rich element (ARE)-binding protein. Overexpression of TTP decreased the mRNA stabil-
ity and protein expression of AHRR, and TTP-overexpressing cells made smaller colonies than the
control. Contrarily, inhibition of TTP by siRNA increased AHRR expression. Analyses of point
mutants of the AREs demonstrated that AREs were responsible for the TTP-mediated destabilization
of AHRR mRNA. RNA EMSA revealed that TTP directly binds to the AHRR 30UTR. Taken together, we
demonstrate that TTP acts as a negative regulator of AHRR and may affect tumor development
through induction of tumor suppressor genes as observed in MDA-MB435.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Post-transcriptional regulation of gene expression is mediatedThe aryl hydrocarbon receptor repressor (AHRR) is a member of
the basic-region helix-loop-helix/PER-Arnt-SIM (bHLH/PAS) pro-
tein family and represses the transcriptional activity of AHR (aryl
hydrocarbon receptor) by competing heterodimer formation with
the AHR nuclear translocator (ARNT) and binding to the xenobiotic
response element (XRE) [1]. The expression of AHRR in tissues has
been reported in several studies [2,3]. The levels of AHRR mRNA
expression is high in the lung, ovary, spleen, and pancreas, how-
ever, it is poorly expressed in the small intestine, liver, kidney, co-
lon and heart.
The AHR is a ligand-activated transcription factor that mediates
a pleiotropic response to various environmental toxins [4], such as
benzo[a]pyrene, and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
[5]. The AHR pathway regulates various physiologic mechanisms,
including drug metabolism, xenobiotic detoxiﬁcation, teratogene-
sis, immunosuppression and tumor promotion [6–8]. Moreover,
there is evidence that the AHR pathway is implicated in promoting
tumors from different anatomical origins [9,10]. In recent studies,
AHR was reported as a tumor suppressor from the observation that
AHR-knockout mice have inhibited prostate and liver carcinogene-
sis [11,12].by AREs located in the 30-untranslated region (30UTR) of a variety
of short-lived mRNAs such as cytokines and proto-oncogenes
[13]. The destabilizing mechanism of AREs is mediated by various
ARE binding proteins [14]. Tristetraprolin (TTP), a well-character-
ized ARE-binding protein, accelerates degradation of a number of
ARE-containing transcripts [15] and may control cancer cell
growth [16,17]. We have investigated if low expression of TTP cor-
relates with increased expression of proto-oncogenes in various
cancers in recent reports [18–22].
In the present study, we investigated the role of TTP in the reg-
ulation of AHRR gene expression in a human breast cancer cell line.
Our data demonstrate that overexpression of TTP decreased AHRR
expression in MDA-MB435 cells. On the other hand, inhibition of
TTP by siRNA increased AHRR expression. AHRR mRNA contains
two AREs in the 30UTR and TTP promoted the decay of AHRR mRNA
through direct binding to the 30UTR of AHRR. Our results show that
AHRR mRNA is a physiological target of TTP and suggest that TTP
regulation of AHRR transcript stability may modulate the effect
of this protein on cell proliferation.
2. Materials and methods
2.1. Cells
Human breast cancer cell lines MCF7, ZR-75-1, MDA-MB231
and MDA-MB435 were purchased from the American Type Culture
H.H. Lee et al. / FEBS Letters 587 (2013) 1518–1523 1519Collection (Manassas, VA) and were maintained in RPMI 1640
media supplemented with 10% FBS (HyClone, Rogan, UT) at 37 C
in a humidiﬁed atmosphere of 5% CO2.
For the MTT cell proliferation assay, cells were plated in tripli-
cate at 1  104 cells/well in 96-well culture plates in RPMI1640.
At the indicated times, CellTiter 96 Aqueous One Solution Reagent
(Promega, Madison, WI) was added to each well according to the
manufacturer’s instructions and absorbance at 490 nm (OD490)
was determined for each well using a Wallac Vector 1420 Multila-
bel Counter (EG&G Wallac, Turku, Finland).
For soft agar cologenic assay, cells were resuspended in 3 ml of
RPMI1640 containing 10% FBS and 0.35% agarose and plated in
6 cm dishes with 3 ml of pre-solidiﬁed RPMI1640 in 0.7% agar con-
taining 10% FBS. Dishes were incubated at 37 C for 2 weeks, and
colonies larger than 0.1 mm in diameter were counted.
2.2. Plasmids and siRNAs
The pcDNA6/V5-TTP construct has been described previously
[20]. Two oligonucleotides containing ATTTA motifs of the AHRR
mRNA 30UTR were synthesized at Integrated DNA Technologies
(Coralville, IA). The oligonucleotides sequences are as follows: Oli-
go-ARE-WT (TCGAGCATGCTGAGCATGGCACACTTCTGGCCTCTGGGC
ATTTATGGATTTAAGACCAGGATGGTATTTCAGAAGCTTCCCACTTCCG
C, GGCCGCGGAAGTGGGAAGCTTCTGAAATACCATCCTGGTCTTAAAT
CCATAAATGCCCAGAGGCCAGAAGTGTGCCATGCTCAGCATGC).
Mutant oligonucleotides of ARE1 and ARE2 in which ATTTA
pentamers were substituted with AGCGA were also synthesized.
The oligonucleotides were ligated into the XhoI/NotI site of the psi-
CHECK2 Renilla/ﬁreﬂy dual-luciferase expression vector (Promega,
Madison, WI).siRNAs against human TTP (TTP-siRNA) (siTTP) and
control siRNA (scRNA) were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA).
2.3. Transfections and luciferase assay
Cells (5  106) were transfected with the various plasmid con-
structs using Fugene6HD (Promega, Madison, WI) and with siRNAs
using jetPRIME (Polyplus, NY) according to the manufacturer’s
instructions.
Lysates of the transfected cells were mixed with luciferase assay
reagent (Promega, Madison, WI) and the chemiluminescent signal
was measured in a Wallac Victor 1420 Multilabel Counter (EG&G
Wallac, Turku, Finland). Renilla luciferase activity of psiCHECK2/
AHRR-ARE-WT was normalized to ﬁreﬂy luciferase in each sample.
2.4. Electrophoretic Mobility Shift Assay (EMSA)
The biotinylated RNA probes for wild-type (Oligo-ARE-WT, 50
CCUGUAUUUAUUUG-AGCUAUUUAAGGAUCUAUUUAUGUUUAAG-
UAUUUAGAAAA-30) and mutant (Oligo-ARE-MUT, 50CCUGUAGCAU
UUGAGCUAGCGAAGGAUCUAGCAUGUUUAAGUAGCGAGAAAA-30)
were synthesized by Samchully Pharm. Co., Ltd. (Seoul, Korea).
Cytoplasmic extracts were prepared from MDA-MB435 cells
using NE-PER Nuclear and Cytoplasmic extraction Reagent
(Thermo Pierce Biotechnology Scientiﬁc, Rockford, IL). RNA EMSA
was performed using the Lightshift Chemoluminescent EMSA Kit
(Thermo Pierce Biotechnology Scientiﬁc, Rockford, IL) according
to the manufacturer’s instructions. Brieﬂy, 10 fmol of biotinylated
RNA was combined with 4 lg of cytoplasmic protein from cells in
a binding buffer. For the supershift EMSA, anti-TTP antibody
(ab36558, Abcam, Cambridge, MA) or control antibody (Sigma,
Louis, MO) was added to the reaction mixture. After the addition
of antibodies, reaction mixtures were incubated overnight on ice.
The reaction mixtures were resolved on 5% non-denaturing
polyacrylamide gels in 0.5 Tris borate/EDTA buffer. Gels weretransferred to nylon membrane (Hybond™-N+; GE Healthcare
Bio-Sciences Corp. Piscataway, NJ) in 0.5 Tris Borate/EDTA at
100 V and 4 C for 1 h.
The RNAs were cross-linked to the membrane and detected
using streptavidin-horseradish peroxidase binding and
chemiluminescence.
2.5. SDS–PAGE analysis and immunoblotting
Proteins were resolved by SDS–PAGE, transferred to Hybond-P
membranes (GE Healthcare Bio-Sciences Corp. Piscataway, NJ),
and probed with the appropriate dilution of anti-TTP antibody
(Sigma, Louis, MO, 1:3000) and anti-AHRR antibody (Abcam,
Cambridge, MA, 1:3000). Immunoreactivity was detected using
the ECL detection system (GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ). Films were exposed at multiple time points to
ensure that images were not saturated.
2.6. Quantitative real-time PCR
For RNA kinetic analysis, we used Actinomycin D and assessed
AHRR mRNA expression by quantitative real-time PCR. Quantita-
tive real-time PCR was performed using the BioRad CFX96 Optics
Module (BioRad, CA) by monitoring the increase in ﬂuorescence
of the SYBR Green dye (iQ SYBR green supermix, Biorad, CA). Spec-
iﬁcity of each primer pair was conﬁrmed by melting curve analysis
and agarose gel electrophoresis. PCR primer pairs were as follows:
TTP: CGCTACAAGACTGAGCTAT, GAGGTAGAACTTGTGACAGA; AH
RR: CTTAATGGCTTTGCTCTGGTCG, TGCATTACATCCGTCTGATGGA.
2.7. Statistics
For statistical comparisons, P-values were determined using the
Student’s t-test.
3. Results
3.1. Overexpression of TTP reduces the expression level of AHRR and
enhances the decay of AHRR mRNA in MDA-MB435 cells
TTP is involved in the degradation of a number of genes re-
quired for cell growth and proliferation which contain an ARE
within their 30UTR [23,24]. Analysis of the human AHRR mRNA
30UTR revealed the presence of two ARE motifs. To determine
whether TTP expression is reciprocally related with AHRR expres-
sion in human breast cancer cell lines, we analyzed the expression
of TTP and AHRR in four human breast cancer cell lines. Cell lines
with high TTP expression levels (MCF7 and ZR-75-1) showed rela-
tively low expression of AHRR, hence cells (MDA-MB231 and MDA-
MB435) with low TTP expression levels showed relatively high le-
vel of AHRR expression (Fig. 1A), suggesting a inverse correlation
between TTP expression and AHRR expression in human breast
cancer cell lines. We next examined whether TTP affects the
expression of AHRR; we transiently transfected MDA-MB435 cells
with pcDNA6/V5-TTP (MDA-MB435/TTP). As a negative control,
MDA-MB435 cells were transfected with an empty pcDNA6/V5
vector (MDA-MB435/pcDNA). The expression levels of AHRR were
checked by RT-PCR and Western blot analysis (Fig. 1B). Our results
showed that the overexpression of TTP signiﬁcantly reduced the
expression of AHRR.
To test whether the down-regulation of TTP effects AHRR
expression, we used siRNA against TTP to reduce the expression le-
vel of TTP in MCF7 cells, which most highly expressed TTP among
the four human breast cancer cell lines. Down-regulation of TTP by
treatment with siTTP signiﬁcantly increased the expression level of
AHRR (Fig. 1C). However, treatment with non-speciﬁc siRNA
Fig. 1. TTP inhibits AHRR expression in human breast cell lines. (A) The level of TTP and AHRR expression in four human breast cancer cell lines were determined by Western
blot analysis. MCF7 cells with high TTP expression and low AHRR expression and MDA-MB435 cells with low TTP expression and high AHRR expression were selected for
further studies. (B) MDA-MB435 cells were transfected with pcDNA6/V5-TTP or pcDNA6/V5 or (C) TTP-siRNA (siTTP) or control-siRNA (scRNA). Expression of TTP and AHRR in
MCF7 cells were determined by real-time PCR and Western blot analysis. b-Actin was detected as a loading control for real-time PCR and Western blot analysis, respectively.
Results shown on the graph represent means ± S.D. of three independent experiments (⁄P < 0.05; ⁄⁄P < 0.01).
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nor did it induce a change in AHRR expression. Collectively, these
results indicate that the expression of AHRR is down-regulated
by TTP in human breast cancer cells.
3.2. TTP destabilizes AHRR mRNA
We next determined whether TTP overexpression decreases the
stability of AHRR mRNA. The half-life of AHRR mRNA was mea-
sured in MDA-MB435 cells transfected with pcDNA6/V5-TTP or
empty pcDNA6/V5 control vector by quantitative real-time PCR.
The overexpression of TTP in MDA-MB435 cells was conﬁrmed
by Western blot analysis (Fig. 1A). While AHRR mRNA was stable
until 2 h after Actinomycin D treatment in empty vector transfec-
ted cells (MDA-MB435/pcDNA), the half-life was signiﬁcantly re-
duced at 2 h after treatment in TTP transfected cells (MDA-
MB435/TTP) (Fig. 2A). Our data indicate that the elevated TTP
expression contributes to decrease of AHRR expression levels
through the destabilization of AHRR mRNA.
3.3. Overexpression of TTP decreases the expression level of luciferase
mRNA containing the AHRR 30UTR
To determine whether the 30UTR of AHRR mRNA is required for
TTP-mediated destabilization of AHRR mRNA, we co-transfected
MDA-MB435 cells with pCDNA6/TTP and a luciferase reporter gene
linked to the AHRR 30UTR fragment containing two AREs in the
plasmid psiCHECK (psiCHECK2/AHRR-ARE-WT). Luciferase activity
was dramatically inhibited in MDA-MB435 cells which were trans-fected with the pcDNA6/TTP compared to that of MDA-MB435 cells
with the empty vector pcDNA6/V5 (Fig. 2B). We checked whether
the two ARE motifs in the 30UTR are responsible for TTP activity by
comparing WT-ARE and ARE-MUT (Section 2). Compared with WT-
ARE, the ARE-MUT construct did not respond to TTP (Fig. 2C). These
results demonstrated that the 30UTR of AHRR mRNA has a role in
TTP-mediated down-regulation of AHRR.
3.4. TTP binds to AREs within the AHRR mRNA 30UTR
To determine whether TTP interacts with two AREs of the AHRR
30UTR, RNA EMSA was conducted using a biotinylated RNA probe
containing the wild-type AREs of the AHRR 30UTR (Fig. 3A). The
RNA probe for RNA EMSA is the same oligonucleotide for the lucif-
erase assay (Fig. 2B). RNA EMSA analysis using cytoplasmic ex-
tracts of MDA-MB435/TTP cells showed RNA–protein binding for
the wild-type motif (Fig. 3A). This RNA–protein complex was re-
duced with increasing concentrations of TTP-antibody preincu-
bated in the reaction mixture. There was no change when the
mixture was preincubated with an anti-IgG as a negative control
(Fig. 3A). Moreover, competitive RNA-binding experiments with
unlabeled oligo-ARE-WT were conducted to estimate the afﬁnity
of TTP to the AHRR-ARE. Gel shift assays were performed with dif-
ferent concentrations of unlabeled competitor AHRR-ARE RNA
using the mixtures of cytoplasmic extracts of MDA-MB435/TTP
cells and the biotin-labeled AHRR-ARE probe (Fig. 3B). An increase
of unlabeled AHRR-ARE resulted in loss of RNA–protein complex
(Fig. 3B). These data indicate that TTP directly interacts with the
oligo-ARE-WT of the AHRR mRNA 30UTR.
Fig. 2. TTP destabilizes AHRR mRNA. (A) MDA-MB435 cells were transfected with pcDNA6/V5-TTP or pcDNA6/V5. Expression of AHRR mRNA in MDA-MB435 cells was
determined by quantitative real-time PCR at the indicated times after addition of 5 lg/ml actinomycin D. Results shown on the graph represent means ± S.D. of three
independent experiments (⁄⁄P < 0.01). (B) Schematic representation of the luciferase reporter constructs used in this study. Oligonucleotides (Oligo) derived from AHRR
mRNA 30UTR were cloned down-stream of the luciferase reporter gene in the psiCHECK2 luciferase expression vector. The white circles represent the wild-type (w)
pentameric motif AUUUA and the black circles represent the mutated (m) motif AGCGA. (C) Inhibition of the luciferase reporter containing AHRR 30UTR by TTP
overexpression. MDA-MB435 cells were co-transfected with luciferase reporters containing two AREs from the AHRR mRNA 30UTR (Oligo-ARE-WT and Oligo-ARE-MUT) and
pcDNA/V5-TTP or empty pcDNA/V5 control vector. Cells were harvested and Renilla luciferase activity was normalized to ﬁreﬂy activity. The luciferase values obtained from
cells cotransfected with luciferase construct and pcDNA6/V5 were set to 1. Results shown on the graph represent the mean ± S.D. of three independent experiments (⁄P < 0.05;
⁄⁄⁄P < 0.001).
Fig. 3. TTP directly binds to AREs within the AHRRmRNA 30UTR. (A) An RNA EMSA was performed by mixing cytoplasmic extracts containing 4 lg of total protein fromMDA-
MB435/TTP cells with 10 fmol of biotinylated wild type probe. Anti-TTP and control antibody was added to the reaction mixtures. (B) 10 lg of cytoplasmic extracts from
MDA-MB435/TTP were incubated with 10 fmol of a biotinylated AHRR ARE RNA probe in the presence of increasing amounts of unlabeled AHRR ARE RNA. The binding
reactions were then separated by electrophoresis on a 5% polyacrylamide gel under non-denaturing conditions. Arrows indicate the position of the TTP-containing band.
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We also examined whether the overexpression of TTP affects
the proliferation of cancer cells. We compared the growth rates be-
tween the MDA-MB435/pcDNA and MDA-MB435/TTP transfected
cells. Overexpressed TTP signiﬁcantly suppressed the growth of
MDA-MB435 cells compared with that of MDA-MB435 transfected
with control vector (Fig. 4A). In addition, down-regulation of AHRR
by TTP resulted in inhibition of anchorage-independent growth in
clonogenic assays (Fig. 4B). TTP-overexpressing cells made smallersize colonies than control cells (bottom panel of Fig. 4B). In previ-
ous reports, TTP was shown to control cell growth through the
destabilization of the AHR pathway-related tumor suppression
genes, such as GADD45 and CYP1A1 [25]. Therefore, we also deter-
mined whether the reduced level of AHRR by TTP effects the
expression of AHR pathway-related genes. We examined the
expression levels of these genes in MDA-MB435 cells by real-time
PCR (Fig. 4C). The induction of CYP1A1 and GADD45A were deter-
mined in MDA-MB435/TTP cells and showed some elevation in
expression. These results may suggest that the down-regulation
Fig. 4. TTP suppresses the growth of MDA-MB435 cells in vitro through inhibition of AHRR expression. (A) In vitro proliferation of MDA-MB435/pcDNA and MDA-MB435/TTP
cells. Cells were seeded at 1  104 cells per well in 96-well plates. Cell viability was performed at the indicated times using a MTT cell proliferation assay. The data represent
the mean ± S.D. of three different experiments (⁄P < 0.01). (B) Colony formation assay of MDA-MB435/pcDNA and MDA-MB435/TTP cells. Cells were seeded at 1  104 cells in
6 cm dishes. After incubation for 2 weeks, colonies were counted. Results shown on the graph represent the mean ± S.D. of three independent experiments (⁄P < 0.01). Bottom
panel: original magniﬁcation, 40. (C) Expression of CYP1A1 and GADD45A in MDA-MB435/pcDNA and MDA-MB435/TTP cells were determined by real-time PCR. b-Actin
was detected as a loading control for real-time PCR. Graph data represent the mean ± S.D. of three independent experiments (⁄P < 0.01).
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creased expression of tumor suppressor genes.
4. Discussion
The expression of AHR pathway related genes, such as AHR,
AHRR and ARNT, are tightly regulated [26]. Upon AHR ligand bind-
ing with TCDD, the TCDD/AHR complex translocates to the nucleus
and dimerizes with the AHR nuclear translocator (ARNT). The AHR-
ARNT complex alters the transcription of XRE containing genes.
Until now, the mechanism by which the AHR pathway is regulated
remains unclear.
TTP is one of the ARE-binding proteins that promote degrada-
tion of ARE-containing mRNAs. ARE-containing genes regulate
oncogenic growth potential, including cyclins, growth factors,
and proto-oncogenes [27,28]. Recent studies have reported that
TTP expression inhibits the growth of tumor cells through degrada-
tion of mRNAs involved in oncogenic growth such as c-fos, c-myc,
cyclinD1, VEGF, and COX-2 mRNAs [17,29,30].
We ﬁrst investigated the relation between gene regulation of
the AHR pathway and TTP expression. We found the ARE sequence
in the 30-UTR sequence of these genes are involved in the AHR
pathway. The expression of AHRR mRNA was more dramatically
decreased in TTP transient-transfected MDA-MB435 cells than
AHR and ARNT. We found that TTP enhanced the decay of AHRR
mRNA through direct binding to the AREs within the AHRR 30UTR.
AHRR mRNA contains two AUUUA pentamers within its 30UTR. Our
mutation analysis of the AHRR 30UTR demonstrates that these AREs
in the 30UTR are essential for the response to TTP.
Previously, we reported that TTP expression was signiﬁcantly
reduced in specimens of surgically resected colonic adenocarci-noma and that overexpression of TTP suppresses the growth of hu-
man colon cancer cells xenografted into nude mice in vivo [23]. So
we suggest that the high expression of TTP may decrease AHRR
mRNA expression in normal cells. This inhibition induces AHR acti-
vation via reducing competition with AHRR and results in up-reg-
ulation of XRE-containing genes, such as, CYP1A1 and GADD45A.
CYP1A1 is important in the metabolism of xenobiotics or carcino-
gens [31]. CYP1A1 encodes a member of the cytochrome P450
superfamily of enzymes that catalyze many reactions involved in
drug metabolism and synthesis of cholesterol, steroids and other
lipids, thus initiating or promoting tumorigenic processes. It has
been reported that the CYP1A1 expression was detected in normal
and cancerous breast tissue [32] and regulated through the AHR
pathway [33]. In addition to CYP1A1, the expression level of GAD-
D45A was also increased in TTP overexpressing MDA-MB435 cells.
Growth arrest and DNA-damage-inducible alpha-GADD45A plays a
key role in regulating the cellular response to genotoxic and onco-
geninc stress [34] and mediates cell cycle control [35], DNA repair
[36], and cell survival [37]. It can be a candidate breast cancer sus-
ceptibility gene mechanistically related to DNA repair [38].
In conclusion, this study demonstrates that AHRR contains ARE
sequences within its 30UTR, and AHRR mRNA is destabilized by di-
rect binding of TTP to AHRR mRNA at the AREs. An outcome of an
excess of AHRR may be many tumor promoting events, and activity
of TTP for the inhibition of AHRR may have wide-ranging clinical
implications.
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